Abstract
With great interest, we read the paper by Gyongyosi et al. 1 who describe the results of the ReoPro-BRIDGING trial. However, we feel that the study results should be interpreted with caution. The primary endpoint is the corrected TIMI frame count (CTFC) of the infarct related vessel (IRV) at initial angiography. However, the limitation of CTFC is that it can only be measured in patients with TIMI 2 flow or more, as the dye will not reach …
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call